Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study

References

• Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15: 569–574.
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, . Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917.
   PubMed Web of Science ®Google Scholar
• Kume H, Yamazaki T, Abe M, . Epidemiology of visceral mycoses in patients with leukemia and MDS-analysis of the data in annual of pathological autopsy cases in Japan in 1989, 1993, 1997 and 2001. Nippon Ishinkin Gakkai Zasshi 2006; 47: 15–24.
   Google Scholar
• Koch S, Hohne FM, Tietz HJ. Incidence of systemic mycoses in autopsy material. Mycoses 2004; 47: 40–46.
   Google Scholar
• Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781–805.
   PubMed Web of Science ®Google Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358–366.
   PubMed Web of Science ®Google Scholar
• Denning DW, Riniotis K, Dobrashian R, . Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37: S265–280.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, . Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327–360.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Ruutu P, Niskanen L, . Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997; 19: 801–808.
   PubMed Web of Science ®Google Scholar
• Chamilos G, Luna M, Lewis RE, . Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 2006; 91: 986–989.
   PubMed Web of Science ®Google Scholar
• Martino R, Subira M, Rovira M, . Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475–482.
   PubMed Web of Science ®Google Scholar
• Kristan SS, Kern I, Music E. Invasive pulmonary aspergillosis. Respiration 2002; 69: 521–525.
   Google Scholar
• Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp.Med Mycol 2005; 43: S207–238.
   PubMed Web of Science ®Google Scholar
• Tomishima M, Ohki H, Yamada A, . FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. J Antibiot (Tokyo) 1999; 52: 674–676.
   PubMed Web of Science ®Google Scholar
• Tawara S, Ikeda F, Maki, K, . In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44: 57–62.
   PubMed Web of Science ®Google Scholar
• Hatano K, Morishita Y, Nakai T, . Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus. J Antibiot (Tokyo) 2002; 55: 219–222.
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42: 1171–1178.
   PubMed Web of Science ®Google Scholar
• Ikeda F, Tanaka S, Ohki H, . Role of micafungin in the antifungal armamentarium. Curr Med Chem 2007; 14: 1263–1275.
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA, . Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519–1527.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein CM, Betts RF, . Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883–893.
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles RL, Chopra R, . A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 47–51.
   PubMed Web of Science ®Google Scholar
• de Wet NT, Bester AJ, Viljoen JJ, . A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21: 899–907.
   PubMed Web of Science ®Google Scholar
• Seibel NL, Schwartz C, Arrieta A, . Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49: 3317–3324.
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, . International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005; 24: 654–661.
   PubMed Web of Science ®Google Scholar
• Kohno S, Masaoka T, Yamaguchi H, . A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36: 372–379.
   PubMed Web of Science ®Google Scholar
• de Wet N, Llanos-Cuentas A, Suleiman J, . A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842–849.
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE, . Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407–1416.
   PubMed Web of Science ®Google Scholar
• Pettengell K, Mynhardt J, Kluyts T, . Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004; 20: 475–481.
   PubMed Web of Science ®Google Scholar
• Tamura K, Urabe A, Yoshida M, . Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma 2009; 50: 92–100.
   PubMed Web of Science ®Google Scholar
• Izumikawa K, Ohtsu Y, Kawabata M, . Clinical efficacy of micafungin for chronic pulmonary aspergillosis. Med Mycol 2007; 45: 273–278.
   PubMed Web of Science ®Google Scholar
• Kohno S, Izumikawa K, Ogawa K, . Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 2010; 61: 410–418.
   PubMed Web of Science ®Google Scholar
• The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [homepage on the Internet]. Switzerland: Harmonised Tripartite Guideline; Current step 4 version [updated 1994 October 27; cited 1995 March]. Clinical Safety Data Management: definitions and Standards for Expedited Reporting E2A. Available from the website: http://www.ich.org/LOB/media/MEDIA436.pdf.
   Google Scholar